Strategic partnerships Hertility has a track record of collaborating with insurers, clinics, and brands (Irish Life Health, London Pregnancy, Sweaty Betty, Moveyourframe) and is actively expanding through NVIDIA collaboration. This indicates strong partnership and channel opportunities for co-marketed services, insurer engagements, and cross-promotional campaigns to accelerate adoption of AI-driven women's health diagnostics.

Global expansion With plans to scale globally in the next six months and a foundation AI model for women's health in development, there is a market-ready case for international enterprise clients, health systems, and regional distributors seeking scalable SaMD-enabled care and AI-assisted diagnostics.

AI core value The company combines multimodal datasets and AI-powered clinical decision support with an integrated patient management system and AI-assisted imaging interpretation. This creates high switching cost for clinicians and a compelling value proposition for healthcare providers needing efficient workflows and scalable care delivery.

Clinical product suite GYN-AI launched in 2025 as a clinical-grade diagnostic tool set for fertility and gynecological conditions, complemented by a SaMD and automated reporting. There is upside in selling to fertility clinics, gynecology practices, insurers, and large employer health programs seeking comprehensive reproductive health solutions.

Market positioning As a data-driven women’s health platform with a largest-in-class dataset and validated accuracy, Hertility targets the underrepresented 51% of the population. This positions it well for enterprise deals with health plans, employer-sponsored programs, and research collaborations focused on prevention, early detection, and personalized care.